NCT00682630View on ClinicalTrials.gov

Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions
Malaria
Interventions
DRUG

pyronaridine artesunate clinical trial reference tablets

Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)

DRUG

pyronaridine artesunate to-be-marketed tablets

Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)

Trial Locations (1)

6864

Cross Research S.A., Phase I Unit, Arzo

All Listed Sponsors
collaborator

Shin Poong Pharmaceuticals

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT00682630 - Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet | Biotech Hunter | Biotech Hunter